SCHEMBL15848977

SCHEMBL15848977

C=C1CCc2c1ccc1c2c2c3c(ccc2n1CCCN(C)C)C(=O)CC3

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 4/20 0.42
TERT O14746 1/20 0.41
HRH1 P35367 2/20 0.39
CHRM2 P08172 1/20 0.39
HTR1A P08908 1/20 0.39
CHRM5 P08912 1/20 0.39
ADRA2A P08913 1/20 0.39
DRD2 P14416 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
CHRM3 P20309 1/20 0.39
DRD4 P21917 1/20 0.39
SLC6A2 P23975 1/20 0.39
HRH2 P25021 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
AVPR2 P30518 1/20 0.39
ADRA1A P35348 1/20 0.39
DRD3 P35462 1/20 0.39
OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13418928 0.93 TERT (0.47) WEE1TERTHRH1CHRM2HTR1A
SCHEMBL14472313 0.85 WEE1 (0.44) WEE1TERTHRH1STAT3HIF1A
SCHEMBL12608688 0.83 TP53 (0.39) WEE1HRH1SLC6A2HIF1ATP53
SCHEMBL17297998 0.82 DRD3 (0.51) WEE1HRH1CHRM2HTR1ACHRM5
SCHEMBL15848958 0.82 SLC6A2 (0.54) WEE1TERTHRH1CHRM2HTR1A
SCHEMBL15848960 0.82 CSF1R (0.47) WEE1TERTHRH1CHRM2HTR1A
SCHEMBL15848969 0.81 TP53 (0.41) WEE1TERTHRH1CHRM2HTR1A
SCHEMBL12608692 0.81 TP53 (0.36) WEE1TP53
SCHEMBL12608700 0.81 TP53 (0.38) TP53
SCHEMBL12608708 0.81 TP53 (0.40) WEE1TP53CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-9108916-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2015-08-18 US disclosed
US-20140303224-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, LLC (US) 2014-10-09 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 WEE1 1071/4885TERT 1333/4885HRH1 846/4885
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 WEE1 1071/4885TERT 1333/4885HRH1 846/4885
US-20140303224-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 WEE1 1071/4885TERT 1333/4885HRH1 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.